Therapy Areas: Oncology
CStone wins EU approval for lung cancer drug
26 July 2024 - Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy fo...
Presage Biosciences starts Phase 0 dosing of first cancer patient with Pure Biologics' PBA-0405
26 July 2024 - Presage Biosciences, a US-based biotechnology company that directly measures activity of oncology drugs within human tumours, announced on Thursday that it has commenced Phase 0 dosing ...
Ipsen, Day One partner on childhood brain tumour drug
25 July 2024 - Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that it has licensed ex-US rights to Day One Biopharmaceuticals' (Nasdaq:DAWN) tovorafenib fo...
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
24 July 2024 - California-based biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Tuesday that the US Food and Drug Administration (FDA) has granted approval to the company'...
Evergreen Nephrology names new director
24 July 2024 - US kidney care speciailst Evergreen Nephrology announced on Tuesday the appointment of David Young to its board of directors.Young has served in leadership roles such as CEO of GenesisC...
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
22 July 2024 - Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.NVL-330 is a novel HER2-se...